Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is an interleukin‑12/23 inhibitor presented as a sterile solution for injection for intravenous administration. It is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease, providing targeted immunomodulation in adult patients who require systemic therapy.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. Our distribution network includes procurement teams in Europe, Asia and the Americas, with dedicated cold‑chain logistics for biologic products.

Ustekinumab is used to modulate the interleukin‑12/23 pathway in several immune‑mediated inflammatory disorders.

- Plaque psoriasis: reduces skin lesions and systemic inflammation in adults with moderate to severe disease, improving quality of life. - Psoriatic arthritis: alleviates joint pain, swelling, and structural damage, helping maintain functional ability. - Crohn's disease: induces and maintains remission of intestinal inflammation in patients with moderate to severe disease who have not responded adequately to conventional therapy.

Adverse reactions may occur with ustekinumab therapy.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the infusion site. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion, or cough. - Headache: mild to moderate intensity, often transient. - Fatigue: general feeling of tiredness without a clear cause. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Serious infections: including tuberculosis or opportunistic infections. - Malignancies: potential increased risk of certain cancers. - Severe hypersensitivity: anaphylaxis or severe allergic reactions. - Exacerbation of inflammatory bowel disease: worsening of Crohn's disease symptoms. - Demyelinating disorders: new or worsening neurological conditions. - Cardiovascular events: rare cases of myocardial infarction or stroke.

Before and during treatment, several safety considerations are recommended.

- Screen for active infections: assess patients for bacterial, viral, or fungal infections prior to initiation. - Monitor for signs of infection: advise patients to report fever, chills, or unexplained illness promptly. - Assess tuberculosis risk: perform TB screening and treat latent infection before therapy. - Evaluate vaccination status: administer required inactivated vaccines before starting ustekinumab. - Avoid live vaccines during therapy: live attenuated vaccines are contraindicated while immunosuppressed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with live vaccines: may cause vaccine‑derived infection. - Combination with other immunosuppressants: heightened risk of severe infections. - Known hypersensitivity to ustekinumab: can trigger life‑threatening allergic reactions.

Moderate Interactions (Monitor Closely): - Concomitant systemic corticosteroids: may amplify immunosuppressive effects. - Use of antibiotics for active infection: monitor therapeutic response and adjust as needed. - Non‑live vaccines: may have reduced efficacy; assess antibody response when appropriate.